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Introduction: Stearoyl-CoA desaturase 1 (SCD1) has been introduced as a novel
therapeutic target in malignancies, including breast cancer. The present study was
designed to investigate the effect of pharmacologic inhibition of SCD1 on fatty acid
profile in tissue explant culture of human breast cancer, and also to compare these
effects with those in adjacent non-neoplastic breast tissue.
Methods: Paired samples of tumor and adjacent non-cancerous tissue were isolated
from twelve patients with infiltrating ductal breast cancer, explant cultured in vitro,
exposed to a highly selective SCD1 inhibitor CAY10566, and investigated with respect
to fatty acid composition by gas liquid chromatography (GLC). Anti-proliferative and
cytotoxic effects were evaluated by quantification of lactate dehydrogenase (LDH)
release and by sulforhodamine B (SRB) measurement.
Results: In the breast cancer tissue, levels of monounsaturated fatty acids (MUFA,
P < 0.001) and arachidonic acid (20:4n-6; P < 0.001) were higher, and the level of
linoleic acid (18:2n-6; P = 0.02) was lower than that in the normal-appearing breast.
While exhibiting no evident cytotoxicity, treatment with SCD1 inhibitor (0.1-1 µM) for
48 hours significantly increased linoleic acid (18:2n-6) in both tumor and adjacent
normal tissue (≃1.2 fold, P < 0.05). However, the levels of MUFA and 20:4n-6, and the
ratio of oleic acid (18:1n-9) to stearic acid (18:0) showed larger fold changes in the
breast cancer than in normal-appearing breast (P = 0.02). SCD1 inhibitor also
repressed growth/proliferation (≃50%, P = 0.001) and elevated SFA (1.4-fold,
P = 0.001) level only in the tumor tissue explant.
Conclusion: There were differences in the fatty acid composition and response to
SCD1 inhibition between the explant cultures from breast cancer compared to adjacent
non-neoplastic tissue. Altered fatty acid composition induced by SCD1 inhibition may
modulate other reactions in de novo fatty acid synthesis, lipogenesis and subsequently
overall breast cancer survival and progression.
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